

DAFTAR PUSTAKA

1. Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. *Semin Thromb Hemost* 2010; 36: 34-40
2. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. *Blood Rev* 2011; 25:271-78.
3. Lutz J, Menke J, Sollinger D, Schinzel, Thürmel K. Haemostasis in chronic kidney disease. *Nephrol Dial Transplant* 2013; 00: 1–12.
4. Zyga S, Kolovos P. Cardiovascular Disease and Chronic Inflammation in mEnd Stage Kidney Disease. *International J of Caring Sciences* 2013; 6(1): 29-36.
5. Wright RS, Reeder GS, Herzog CA. Acute myocardial infarction and renal dysfunction: a high-risk combination. *Ann Intern Med* 2002; 137: 563-70.
6. Yahalom G, Kivity S, Segev S, Sidi Y, Kurnik D. Estimated glomerular filtration rate in a population with normal to mildly reduced renal function as predictor of cardiovascular disease. *Eur J Prev Cardiol* 2014;21(8):941-80
7. Wattanakit K, Cushman M, Stehmann-Breen. Chronic kidney disease increases risk for venous thromboembolism. *J Am Soc Nephrol* 2008;19: 135-40
8. Ocak G, Lijfering WM, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. *J Thromb Haemost* 2013; 11: 627-33.
9. Kumar G, Sakhuja A, Taneja A, Majumdar T, Patel J, Whittle J, et al. Pulmonary embolism in patients with CKD and ESRD. *Clin J Am Soc Nephrol*. 2012; 7: 1584-90.
10. Parikh AM, Spencer FA, Lessard D, Emery C, Baylin A, Linkletter C, et al. Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective. *Am J Kidney Dis* 2011; 58(5): 746-55.
11. Setiabudy RD. Patofisiologi trombosis. Dalam: Hemostasis dan trombosis, ed.4. Setiabudy RD,ed. Balai Penerbit FKUI 2009: 34-47.
12. Moshe S, Francis J, Chitalia V. Thrombosis in the uremic milieu-emerging role of thrombolome. *Semin Dial*. 2015; 28(2):198-205

13. Milburn JA, Ford I, Mutch NJ, Fluck N, Brittenden J. Trombin-anti-trombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis. *Plos One* 2013; 8(7): 1-7.
14. Adcock DM, Bethel MA, Macy PA. *Coagulation handbook*. Austin. 2006.
15. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. *Nephron* 1993; 63(3): 273-8.
16. Rabelink TJ, Zwaginga JJ, Koomans HA, Slxma JJ. Trombosis and hemostasis in renal failure. *Kidney Int* 1994;46:287-96.
17. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on capd and patients on hemodialysis. *Peritoneal Dialysis International* 2001; 1(21): 158-165.
18. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A Bench to bedside view of uremic toxins. *J Am Soc Nephrol* 2008; 19: 863-870.
19. Niwa T. Uremic toxicity of indoxyl sulfate. *Nagoya J Med Sci* 2010; 72: 1-11
20. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl sulfate and indoxyl sulfate predict progression of chronic kidney disease. *Nephro Dial Transplant* 2010: 1-9.
21. Kikuchi K, Itoh Y, Tateoka R. Metabolomic analysis of uremic toxins by liquid chromatography/ electrospray ionization-tandem mass spectrometry. *J Chromatog B* 2010; 878: 1662-8.
22. Liabeuf S, Drüeke TB, Massy ZA. Protein-Bound Uremic Toxins: New Insight from Clinical Studies. *Toxins* 2011, 3, 911-919.
23. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, UGent AP, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. *Kidney Int* 2013; 84: 733-744.
24. Chitalia CV, Shivanna S, Martorell J, Malcells M, Bosch I, Kolandaivelu K et al. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cel tissue factor. *Circulation* 2013; 217: 363-76.

25. Gao C, Xie R, Yu C, Ma R, Dong W, Meng H et al. Thrombotic role of blood and endothelial cells in uremia through phosphatidylserine exposure and microparticle release. *Plos One* 2015; 10(11): 1-16.
26. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temma M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. *Clin J Am Soc Nephrol* 2009; 4: 1551–1558.
27. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ et al. p-Cresyl sulfate and indoxyl sulfate level at different stages of chronic kidney disease. *J Clin Lab Anal* 2011; 25: 191-7.
28. Watanabe I, Koizumi M, Tatebe J, Ikeda T, Morita T. Vascular senescence in chronic kidney disease: association of aryl hydrocarbon receptor activated by indoxyl sulfate. *Recept & clin invest* 2014; 1: 1-6.
29. National Kidney Foundation. KDIGO 2012: Clinical practice guideline for the evaluation and management chronic kidney disease. *Kid Int Supplements* 2013; 3(1): 1-163.
30. Oesman F, Setiabudy RD. Fisiologi hemostasis dan fibrinolisis. Dalam: *Hemostasis dan trombosis*, ed 4. Setiabudy RD,ed. Balai Penerbit FKUI 2009: 1-15.
31. Sjøland JA. *Inflammation and Fibrin Structure in Patients with End-Stage Renal Disease*. Tesis. Denmark. 2007; 1-86
32. Sallée M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. *Toxins* 2014; 6:934-49.
33. Erdem Y, Haznedaroglu IC, Celik I, Yalcin AU, Yasavul U, Turgan C, et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in hemodialysis patients: contribution of arteriovenous fistula. *Nephrol Dial Transplant* 1996;11:1299–305.
34. Mercier E, Branger B, Vecina f, Al-Sabadani B, Berlan J, et al. Tissue Factor coagulation pathway and blood cells activation state in renal insufficiency. *Hematol J* 2001; 2: 18-25.

35. Cetin O, Bekpinar S, Unlucerci Y, Turkmen A, Bayram C, Ulutin T. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. *Clin Nephrol* 2006; 65(2): 97-102.
36. Furie B, Furie BC. Mechanisms of thrombus formation. *N Engl J Med* 2008; 359: 938-49.
37. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease. *Am J Nephrol* 2013;38:136–148.
38. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P. Vascular incompetence in dialysis patients-protein bound uremic toxins and endothelial dysfunction. *Sem in Dialysis* 2011; 24(3): 327-37.
39. Piazza G, Goldhaber SZ, Lessard DM. Venous thromboembolism in patients with symptomatic atherosclerosis. *Thromb Haemost* 2011; 106: 1095-1102.
40. Tripodi A, Mannucci PM. Marker of activated coagulation and their usefulness in the clinical laboratory. *Clin Chemistry* 1996; 42(5): 664-69.
41. Patnaik M, Moll S. Inherited antithrombin deficiency: a review. *Haemophilia* 2008; 14: 1229-39.
42. Glorieux G, Schepers E, Vanholder R. Uremic toxins in chronic renal failure. *Sec Biol Med Sci* 2007; 28(1): 173–204.
43. Lisowska-Myjak B. Uremic Toxins and their effects on multiple organ systems. *Nephron Clin Pract* 2014; 128: 303-11.
44. Kuijpers M, van der Meijden P, Feijge M, Mattheij N, May F, et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. *Atheroscler Thromb Vasc Biol* 2014; 34: 1674-80.
45. Indoxyl sulfate is a nephro-vascular toxin. *J Ren Nutr* 2010; 20(5): S2-6.
46. Viaene L, Annaert P, de Loor H, Poesen R, Evenepoel P, Meijers B. Albumin is the main binding protein for indoxyl sulfate and p-cresyl sulfate. *Biopharm. Drug Dispos* 2013; 34: 165-75.
47. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. *Ther Apher Dial* 2011; 15(2): 120-4.

48. Ito S, Osaka M, Higuchi Y, Nishijima F, Ishii H, Yoshida M. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. *J of Bio Chem.* 2010; 285: 38869-75.
49. Schroeder JC, Dinatale BC, Murray IA. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. *Biochemistry* 2010;49:393–400.
50. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. *Circulation* 2006; 113: 722–731
51. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. *J Am Soc Nephrol* 2014; 25: 1897-1907.
52. Gao C, Ji S, Qi Y, Song w, Cui D, Shi J. Indolic uremic solutes enhanced procoagulant activity of red blood cells through phosphatidylserine exposure and microparticle release. *Toxins* 2015; 7: 4390-4403.
53. Adams MJ, Irish AB, Watts GF, Oostrik R, Dogra GK. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial dysfunction. *Thrombosis Research* 2008; 123: 374-80.
54. Summary Health Statistics: National Health Interview Survey, 2014 Diakses dari <http://www.cdc.gov/nchs/fastats/kidney-disease.htm>
55. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population based studies: systematic review. *BMC Public Health* 2008; 8: 117
56. 7 th Report Of Indonesian Renal Registry 2014. Diakses dari: www.indonesianrenalregistry.org/data/indonesian%20renal%20registry%202014.pdf
57. Islam TM, Fox CS, Mann D, Muntner P. Age related associations of hypertension and diabetes mellitus with chronic kidney disease. *BMC Nephrol* 2009; 10: 17-20
58. Duranton F, Cohen G, Smet RD, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. *J Am Soc Nephrol* 2012; 23: 1258-70.

59. Wu IW, Hsu KH, Sun CY, Tsai CJ, Wu MS, Lee CC. Oral adsorbent AST-120 potentiates the effects of erythropoietin stimulating agents on stage 5 chronic kidney disease patients: a randomized crossover study. *Nephrol Dial Transplant* 2014;29; 1719-27.
60. Ellis RJ, Small DA, Johnson DW, Francis R, Vietta L, Gobe GC, et al. Indoxyl sulphate and kidney disease: causes, consequences and interventions. Centre for kidney disease research. 2014.
61. Viaene L, Thijs L, Jin Y, Liu Y, Gu Y, Meijers B, et al. Heritability and clinical determinants of serum indoxyl sulfate and p-cresyl sulfate, candidate biomarkers of the human microbiome enterotype. *Plos One* 2014; 9(5): 1-7.
62. Benson AK, Kelly SA, Legge R, Ma F, Low SJ. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. *Proc Natl Acad Sci USA* 2010; 107: 18933–18938.
63. Barreto Fc, Barreto DV, Canziani ME, Tomiyama C, Higa A, Mozar A, et al. Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. *J Bras Nefrol* 2014;36(3):289-296
64. Yoshikawa D, Ishii H, Suzuki S, Takhesita K, Kumagai S, Hayashi M, et al. Plasma indoxyl sulfate and estimated glomerular filtration rate association with long term clinical outcome in patients with coronary artery disease. *Circ J* 2014; 78: 2477-82.
65. Nelson K, Thethi I, Cunanan J, Hoppensteadt D, Bajwa R, Fareed J, et al. Upregulation of surrogate markers of inflammation and thrombogenesis in patients with ESRD: pathophysiologic and therapeutic implications. *Clin and Appl Thrombosis/ Hemostasis* 2011; 17(3): 302-04.
66. Alfirevic Z, Alfirevic I. Hypercoagulable state, pathophysiology, classification and epidemiology. *Clin Chem Lab Med* 2010; 48(1): s15-s26.
67. Plat A. Can you recognize a patient at risk for a hypercoagulable state? *JAAPA* 2008; 21(12): 20-26.
68. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. *J of Thrombosis and Haemostasis* 2009; 7(1): 301-04.